NY-IFF
28.7.2021 22:02:12 CEST | Business Wire | Press release
IFF (NYSE: IFF) today announced that Nicolas Mirzayantz, current President, Scent, has been appointed President of IFF’s Nourish division, effective September 1, 2021. Mr. Mirzayantz will succeed Kathy Fortmann, current President, Nourish, who has decided to pursue other opportunities outside of IFF. IFF veteran and current President, Global Consumer Fragrances, Christophe de Villeplee, will assume transition into the role of President, Scent.
“We could not be more pleased to have Nicolas lead our Nourish division,” said IFF Chairman and CEO, Andreas Fibig. “Nicolas is joining a Nourish division with a tremendous opportunity to build on significant sales momentum and strong customer interest in IFF’s differentiated portfolio and capabilities. He has been an invaluable member of our leadership team, with an unparalleled ability to create a culture of innovation and deliver creative and winning solutions to our customers while consistently strengthening the business through growth and margin expansion. Nicolas has transformed our Scent division into the global fragrance leader it is today, and I am confident that he will bring to Nourish the same passion, culture of breakthrough innovation, financial prowess and commitment needed to drive continued momentum with Nourish. I also want to thank Kathy for her leadership at a pivotal time for Nourish and we wish her the best as she embarks on her next chapter.”
Mr. Mirzayantz, who has had a 33-year career with the Company, brings decades of industry experience to his new role. During his 14-year tenure as President of the Scent division, Mr. Mirzayantz led a compound annual growth rate of approximately 5%, while continuously expanding profit margin. Previously, Mr. Mirzayantz served as Regional Manager, North America, during which he led IFF’s North American Flavors and Fragrances division.
As President, Nourish, Mr. Mirzayantz will focus on leveraging the division’s best-in-class product portfolio and world-class innovation to create unmatched solutions for customers that drive industry-leading growth. Together with an incredibly talented Nourish team, Mr. Mirzayantz will partner with customers of all sizes to shape the future of the global food and beverage experience for IFF’s stakeholders.
“Since joining IFF more than 30 years ago, I have had the privilege of working closely together with each of the Company’s divisions, including Nourish,” said Nicolas Mirzayantz, President, Scent. “The opportunity for our Nourish division is significant and I know that I will be joining an impressive, creative team that is laser-focused on delivering industry-defining solutions for our customers. I’m equally pleased to know that Scent will continue its strong momentum with Christophe. I have had the privilege to work with him for the past 22 years and I know firsthand that he has the expertise and experience necessary to successfully lead the division into the future while upholding IFF’s collaborative, innovative and purpose-driven culture.”
Mr. de Villeplee, who currently serves as President, Global Consumer Fragrances, will assume Mr. Mirzayantz’ current role of President, Scent effective September 1, 2021. Drawing upon his long career with IFF and 30 years of experience within the fragrance sector, Mr. de Villeplee will play an instrumental role in leading the Scent division’s continued creative discoveries and scientific breakthroughs, positioning IFF’s Scent division as the industry’s leading fragrance creation and solutions provider.
Added Mr. Fibig: “I firmly believe that Christophe is the right leader for the IFF Scent division. He brings more than two decades of experience growing our customer relationships in consumer and fine fragrance globally and is well-positioned to oversee Scent’s future growth. I am excited to have him join our Executive Committee and know that he will continue to have successes leading our Scent division.”qw
“I am both proud and excited to start my new role as President of IFF’s Scent division and to lead such a passionate group of IFFers,” said Mr. de Villeplee. “Having worked closely with Nicolas for 22 years in the Scent division, I look forward to building on the incredible momentum that we have created to deliver continued innovation and growth for the division and our customers for years to come.”
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005964/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press release
Enterprise software veteran to lead Tacton’s united commercial organization and partner expansion worldwide. Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release
Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu
NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 12:45:00 CEST | Press release
New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store. NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time buil
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
